Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus EVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus EVEX.
ESTRADIOL CYPIONATE vs EVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
Estrogen receptor agonist; binds to and activates nuclear estrogen receptors, leading to gene transcription and cellular effects in target tissues.
1-5 mg intramuscularly every 3-4 weeks.
0.625-1.25 mg orally once daily; or 0.3-0.625 mg vaginally once daily for 21 days with 7 days off.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Terminal elimination half-life is 12-24 hours, with a mean of approximately 18 hours. Due to significant enterohepatic recirculation, the half-life may be prolonged in patients with hepatic impairment or when administered with drugs that inhibit recirculation.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Primarily hepatic metabolism with renal excretion of metabolites; approximately 60% of a dose is excreted in urine as conjugates (glucuronides and sulfates) and 30% in feces via biliary elimination. Less than 5% is excreted unchanged in urine.
Category D/X
Category C
Estrogen
Estrogen